LONDON/MILAN, Nov. 3, 2025 — AAVantgarde Bio has raised $141 million in a Series B financing round, co-led by Schroders Capital and Atlas Venture, with participation from Amgen Ventures, Forbion, and other international investors. The funding will accelerate the company’s clinical-stage gene-therapy programs AAVB-039 for Stargardt disease and AAVB-081 for Usher 1B syndrome, both aimed at preserving or restoring vision in patients with inherited retinal disorders.
Science Significance
This financing supports AAVantgarde’s innovative gene-augmentation platform, designed to deliver large or dual-gene constructs that exceed the size limits of standard AAV vectors. This breakthrough allows researchers to target genetic diseases that were once considered untreatable. AAVB-039 corrects mutations in the ABCA4 gene, responsible for Stargardt disease, while AAVB-081 addresses MYO7A mutations linked to Usher 1B syndrome. The scientific advance strengthens the pipeline of next-generation gene therapies that aim to correct the disease at its genetic root.
Regulatory Significance
AAVantgarde’s lead candidate AAVB-039 has received Orphan Drug Designation from the U.S. FDA and clinical authorization from the UK MHRA, underscoring the program’s rare-disease focus. The company’s regulatory pathway now includes Phase 1/2 clinical studies and expansion of its natural-history STELLA study to further characterize disease progression. These milestones position AAVantgarde as a frontrunner in regulatory advancement within the global gene-therapy landscape.
Business Significance
Advertisement
The $141 million investment represents one of Europe’s largest biotech Series B rounds in 2025, validating investor confidence in AAVantgarde’s technology and long-term growth strategy. With participation from both venture capital and strategic pharma investors, including Amgen Ventures, the financing strengthens the company’s capacity for clinical expansion, manufacturing scale-up, and global collaboration. This influx of capital not only supports scientific progress but also establishes AAVantgarde as a key player in the growing gene-therapy investment ecosystem.
Patients’ Significance
For patients living with Stargardt disease and Usher 1B syndrome, current treatments remain unavailable. AAVantgarde’s gene-therapy programs could offer long-lasting vision restoration and, in the case of Usher 1B, potential improvement in both sight and hearing. These advances offer hope to individuals and families affected by rare retinal disorders, aligning scientific innovation directly with patient benefit and quality of life.
Policy Significance
The Series B financing reflects the increasing alignment of venture capital, biotech policy, and rare-disease incentives. Global regulators and investors are jointly shaping a landscape where gene-therapy innovations can reach patients faster through orphan-drug designations, expedited reviews, and cross-border regulatory cooperation. The deal also underscores the importance of sustainable funding models to ensure continued growth of gene-therapy development worldwide.
AAVantgarde Bio’s $141 million Series B round marks a defining step in bringing gene-based vision restoration therapies to market. With robust scientific foundations, regulatory progress, and strong investor backing, the company is positioned to redefine therapeutic options for inherited retinal diseases. The financing further signals sustained venture-capital interest in next-generation genetic medicine, strengthening the innovation pipeline that bridges science, investment, and patient impact.
Source : AAVantgarde Bio press release
